SCHEMBL2993889

SCHEMBL2993889

Oc1ccnc2[nH]cc(-c3ccncn3)c12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 7/20 0.64
CDK5 Q00535 7/20 0.64
CDK5R1 Q15078 7/20 0.64
CCNT1 O60563 6/20 0.64
CCNA2 P20248 6/20 0.64
CDK9 P50750 6/20 0.64
CCNA1 P78396 6/20 0.64
ROCK1 Q13464 13/20 0.59
CDC42BPB Q9Y5S2 13/20 0.59
ROCK2 O75116 9/20 0.59
CDC42BPA Q5VT25 6/20 0.48
CCNB2 O95067 2/20 0.41
CDK1 P06493 2/20 0.41
CCNB1 P14635 2/20 0.41
PRKACA P17612 2/20 0.41
PRKACG P22612 2/20 0.41
PRKACB P22694 2/20 0.41
GSK3B P49841 2/20 0.41
CCNB3 Q8WWL7 2/20 0.41
PDPK1 O15530 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2996408 0.82 CCNT1 (0.64) CDK2CDK5CDK5R1CCNT1CCNA2
SCHEMBL2988182 0.82 CCNT1 (0.68) CDK2CDK5CDK5R1CCNT1CCNA2
SCHEMBL2997144 0.82 CDK2 (0.64) CDK2CDK5CDK5R1CCNT1CCNA2
SCHEMBL2993897 0.79 CCNT1 (0.65) CDK2CDK5CDK5R1CCNT1CCNA2
SCHEMBL29941740 0.78 CCNT1 (1.00) CDK2CDK5CDK5R1CCNT1CCNA2
SCHEMBL2997834 0.78 CCNT1 (1.00) CDK2CDK5CDK5R1CCNT1CCNA2
SCHEMBL2994119 0.78 CCNT1 (0.64) CDK2CDK5CDK5R1CCNT1CCNA2
SCHEMBL2992890 0.78 CCNT1 (0.60) CDK2CDK5CDK5R1CCNT1CCNA2
SCHEMBL2992172 0.78 CDK5 (0.60) CDK2CDK5CDK5R1CCNT1CCNA2
Meriolin 2 SCHEMBL2999865 0.78 CDK5 (0.70) CDK2CDK5CDK5R1CCNT1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125803-B1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF CENTRE NAT RECH SCIENT (FR) 2013-04-10 EP disclosed
US-20100184790-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184790-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF BAD, PPOX, CASP3 CDK2 127/4885CDK5 15/4885CDK5R1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.